Filing Details

Accession Number:
0000919574-19-004140
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-13 17:20:03
Reporting Period:
2019-06-11
Accepted Time:
2019-06-13 17:20:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949858 Achieve Life Sciences Inc. ACHV In Vitro & In Vivo Diagnostic Substances (2835) 954343413
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1601086 Armistice Capital, Llc 510 Madison Avenue, 7Th Floor
New York NY 10022
No No Yes No
1633584 Ltd. Fund Master Capital Armistice C/o Dms Corporate Services Ltd.
20 Genesis Close, P.o. Box 314
Grand Cayman E9 KY1-1104
No No Yes No
1706140 Steven Boyd C/o Armistice Capital, Llc
510 Madison Avenue, 7Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-06-11 2,200 $3.01 841,576 No 4 S Direct
Common Stock Disposition 2019-06-11 0 $0.00 841,576 No 4 S Indirect See Footnote
Common Stock Disposition 2019-06-11 44,982 $2.85 796,594 No 4 S Direct
Common Stock Disposition 2019-06-11 0 $0.00 796,594 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Indirect See Footnote
No 4 S Direct
No 4 S Indirect See Footnote
Footnotes
  1. The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation (the "Master Fund"), and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.